Salt Lake-based Myriad Genetics Inc. said Tuesday it will begin a second first-phase clinical trial with its cancer drug candidate MPC-6827.
View Comments
The new study will evaluate the potential of the candidate to treat metastatic brain cancer and will be performed at Memorial Sloan-Kettering Cancer Center in New York City.